Nick Rijke, Executive Director of Policy and Research for the MS Society, talks about early treatment for multiple sclerosis.
Learn more about MS here: http://bit.ly/1PBLn0c
Early Treatment for Multiple Sclerosis
What can we help you find today?
” . . . it must be acknowledged that long-term benefits of early DMT [disease modifying treatment] have not yet been definitively demonstrated.
Currently available long-term data are riddled with biases and therefore nearly impossible to interpret. In addition, none of these agents has yet been found to be effective in the nonrelapsing MS patient population. Therefore, we must understand that the relationship between relapse prevention and long-term disability prevention is far from established.”
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.
Farber RS, Sand IK.